ImmunoGen, Inc.
IMGN
株式のランク
#2950
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes... ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer. Another significant candidate, Pivekimab sunirine, a CD123-targeting ADC, is progressing through Phase II studies for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Beyond its clinical efforts, the company's preclinical portfolio includes IMGC936, an ADC being co-developed with MacroGenics, Inc., and IMGN151, another anti-FRa therapeutic. ImmunoGen maintains strategic collaborations with a range of key industry players, such as Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. Founded in 1980, ImmunoGen, Inc. is headquartered in Waltham, Massachusetts.
株価
$31.23
最終同期: 2024-02-13
時価総額
$6.24B
変化（1日）
0.00%
変化（1年）
-0.03%
国
US
取引 ImmunoGen, Inc. (IMGN)
カテゴリー
Healthcare
の時価総額 ImmunoGen, Inc.(IMGN)
時価総額: $6.24B
October 2026時点で、ImmunoGen, Inc. の時価総額は $6.24B です。これは、当社のデータによると、ImmunoGen, Inc. が世界で2950th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
ImmunoGen, Inc. の時価総額の履歴（2023 から 2026 まで）
